CA2164733A1 - Methods and compositions for lowering intraocular pressure - Google Patents

Methods and compositions for lowering intraocular pressure

Info

Publication number
CA2164733A1
CA2164733A1 CA002164733A CA2164733A CA2164733A1 CA 2164733 A1 CA2164733 A1 CA 2164733A1 CA 002164733 A CA002164733 A CA 002164733A CA 2164733 A CA2164733 A CA 2164733A CA 2164733 A1 CA2164733 A1 CA 2164733A1
Authority
CA
Canada
Prior art keywords
quinine
eye
intraocular pressure
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002164733A
Other languages
English (en)
French (fr)
Inventor
Nino Sorgente
Charles Bakhit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vide Pharmaceuticals
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/096,799 external-priority patent/US5629345A/en
Application filed by Individual filed Critical Individual
Publication of CA2164733A1 publication Critical patent/CA2164733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002164733A 1993-06-08 1994-06-03 Methods and compositions for lowering intraocular pressure Abandoned CA2164733A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7380293A 1993-06-08 1993-06-08
US08/096,799 US5629345A (en) 1993-07-23 1993-07-23 Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US08/073,802 1993-07-23
US08/096,799 1993-07-23

Publications (1)

Publication Number Publication Date
CA2164733A1 true CA2164733A1 (en) 1994-12-22

Family

ID=26754897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002164733A Abandoned CA2164733A1 (en) 1993-06-08 1994-06-03 Methods and compositions for lowering intraocular pressure

Country Status (5)

Country Link
EP (1) EP0724443A4 (ja)
JP (1) JPH08511024A (ja)
AU (1) AU7099194A (ja)
CA (1) CA2164733A1 (ja)
WO (1) WO1994028900A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
ID19891A (id) * 1996-08-02 1998-08-20 Senju Pharma Co Komposisi gangguan peredaran anti-okular
CA2396319A1 (en) 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
EP1515974A4 (en) 2002-06-17 2007-02-28 Merck & Co Inc NOVEL MAXI K CHANNEL BLOCKERS, METHODS OF USE, AND METHODS OF MANUFACTURING THE SAME
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN1791402A (zh) 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
CA2537119A1 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN1842335A (zh) 2003-09-04 2006-10-04 默克公司 用于治疗高眼压的眼用组合物
EP1663987B1 (en) 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1771170A4 (en) 2004-07-20 2009-07-08 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558728B1 (fr) * 1984-01-26 1986-06-06 Sanofi Sa Composition pharmaceutique antipaludeenne a base de quinine, quinidine et cinchonine
FR2568473B1 (fr) * 1984-08-03 1987-05-15 Vaillant Defresne Laboratoire Nouvelle composition a base de formiate de quinine
US4895807A (en) * 1986-12-31 1990-01-23 Cherksey Bruce D Membrane channel protein and related therapeutic compounds
CA2044853C (en) * 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
CA2044855A1 (en) * 1990-07-20 1992-01-21 Kerry P. S. J. Murphy Method for treating insult to neurons prone to parkinson's degeneration employing an atp-sensitive potassium channel blocker
CA2139779A1 (en) * 1992-07-17 1994-02-03 Ralph A. Rivero Substituted biphenylmethylimidazopyridines

Also Published As

Publication number Publication date
AU7099194A (en) 1995-01-03
EP0724443A4 (en) 1997-09-10
EP0724443A1 (en) 1996-08-07
WO1994028900A1 (en) 1994-12-22
JPH08511024A (ja) 1996-11-19

Similar Documents

Publication Publication Date Title
Lee et al. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey.
KR100452715B1 (ko) 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
JP5174777B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US4476140A (en) Composition and method for treatment of glaucoma
EP0389995B1 (en) Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
EP0365662B1 (en) Antiglaucoma compositions containing combinations of alpha-2 agonists and beta-blockers
EP0825863B1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
SK123996A3 (en) Ophthalmic composition with decreased viscosity
EP1568382B1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER
CA2164733A1 (en) Methods and compositions for lowering intraocular pressure
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
EP0399791A1 (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
JP2824863B2 (ja) α▲下１▼―ブロッカー点眼剤
CA2206123A1 (en) Use of chloride channel blockers for reducing intraocular pressure
WO1989010757A1 (en) New ophthalmic preparation for treating glaucoma
US5049587A (en) Ophthalmic solution for intraocular pressure adjustment
KR100610997B1 (ko) 녹내장과 연관된 시신경 퇴화 방지용 약제를 제조하기 위한 나트륨 채널 차단제의 용도
US5965620A (en) Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5079253A (en) Composition for the topical treatment of glaucoma or ocular hypertension
US5629345A (en) Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
EP1410808A1 (en) Optic nerve protecting agents containing alpha 1 receptor blocker as the active ingredient
CZ294314B6 (cs) Topické oftalmické léčivo
CA2132102A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists
EP0608604A1 (en) Ajmaline to reduce elevated intraocular pressure

Legal Events

Date Code Title Description
FZDE Dead